Organization
Eisai Co., Ltd.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Eisai Co., Ltd.
... it had entered into a Global Licensing Agreement ("the Agreement") with Eisai Co., Ltd. ("Eisai"), a global pharmaceutical company with a focus on serving patients ...
... in Japan. EA Pharma, a subsidiary of the global pharmaceutical company Eisai Co., Ltd. and the exclusive licensee of elobixibat for the treatment of gastrointestinal ...
... Muscle Relaxant Drugs Sunovion Submits Drug Application to the FDA for Dasotraline Eisai Pharmaceuticals Unveils Anti-Epilepsy Drug Fycompa Eisai's Antiepileptic Drug gets Approval from FDA ...
... now moving in to threaten that status. Merck’s Keytruda, in tandem with Eisai’s Lenvima, has nabbed the FDA’s breakthrough therapy designation as a potential treatment ...
... Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced today that its Chinese ...
... Dohme), AstraZeneca, Pfizer and, Takeda. Very few companies like Bristol-Myers Squibb, Novartis, Eisai and Roche are investing on the rare variant, the non-clear cell RCC. ...
... Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced that its in-house discovered ...
... Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') and Biogen Inc. (NASDAQ: BIIB) ...
... Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) ...
... Eisai and Biogen’s hopes of an early positive read-out for anti-amyloid beta drug ...
... Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced that it has created ...
... TOKYO - Eisai Co., Ltd. announced today that Aricept (donepezil hydrochloride) has been approved for the ...
... New Jersey & STAMFORD - Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. presented results from two research studies on ...
... Japan’s Eisai, which is battling England’s drug cost watchdog to win approvals for its ...
... Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced that it has submitted ...
... benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the ...
... Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced today that the China ...
... we learn from past failures? What are the chances of success for Biogen/Eisai's aducanumab and the other beta-amyloid mAbs, as well as the BACE inhibitors, ...
... Eisai, which was hoping the drug cost regulator in England would approve its ...
... Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') has announced that it received ...
... Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') has announced that its German ...
... avert problems in the supply of medicines. AstraZeneca, an Anglo-Swedish company, and Eisai, a Japanese one, have already started to duplicate their testing and approval ...
... market leader? Comparing 10 major RCC treatments from Amgen, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Novartis, Pfizer, and Roche, this report reveals: - How oncologists rate ...
... the first Vice President and Global Therapeutic Area Head in Oncology at Eisai, a role in which she advanced five original compounds into Phases I ...
Want to see the full history on Eisai Co., Ltd.? Upgrade to RelSci Pro now!
Start My Free Trial